摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-bromo-4-chloro-1-methyl-1H-benzo[d]imidazole | 1357159-33-1

中文名称
——
中文别名
——
英文名称
5-bromo-4-chloro-1-methyl-1H-benzo[d]imidazole
英文别名
5-Bromo-4-chloro-1-methylbenzimidazole
5-bromo-4-chloro-1-methyl-1H-benzo[d]imidazole化学式
CAS
1357159-33-1
化学式
C8H6BrClN2
mdl
——
分子量
245.506
InChiKey
ZKMKWHYTYYLODK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    5-bromo-4-chloro-1-methyl-1H-benzo[d]imidazole2-双环己基膦-2',6'-二甲氧基联苯四(三苯基膦)钯 、 palladium diacetate 、 sodium carbonate 、 potassium carbonate 作用下, 以 1,4-二氧六环乙腈 为溶剂, 反应 3.33h, 生成
    参考文献:
    名称:
    Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
    摘要:
    Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.
    DOI:
    10.1021/jm201394e
  • 作为产物:
    描述:
    4-溴-3-氯-N-甲基-2-硝基苯胺 在 sodium dithionite 作用下, 以 乙醇 为溶剂, 反应 1.08h, 生成 5-bromo-4-chloro-1-methyl-1H-benzo[d]imidazole
    参考文献:
    名称:
    Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
    摘要:
    Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.
    DOI:
    10.1021/jm201394e
点击查看最新优质反应信息

文献信息

  • NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
    申请人:Diaz Caroline Jean
    公开号:US20100222345A1
    公开(公告)日:2010-09-02
    This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
    这项发明涉及新型化合物,它们是阿片受体的拮抗剂或逆向激动剂之一,以及含有它们的药物组合物,它们的制备过程,以及它们在治疗中的应用。
  • Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT
    作者:Jason G. Kettle、Simon Brown、Claire Crafter、Barry R. Davies、Phillippa Dudley、Gary Fairley、Paul Faulder、Shaun Fillery、Hannah Greenwood、Janet Hawkins、Michael James、Keith Johnson、Clare D. Lane、Martin Pass、Jennifer H. Pink、Helen Plant、Sabina C. Cosulich
    DOI:10.1021/jm201394e
    日期:2012.2.9
    Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed predictable DMPK properties, and one such compound demonstrated pharmacodynamic knockdown of phosphorylation of AKT and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.
查看更多